Categories

I-CARE Early Covid (3) I-CARE Flu and RSV (1) I-PREVENT (28) I-RECOVER Long Covid (3) I-RECOVER Post-Vaccine (3) MATH+ (20)

Tags

25-hydroxyvitamin D (2) 25‐HYDROXY VITAMIN D (2) Ambulatory treatment (2) Anti-inflammatory (2) Anti-Inflammatory Agents (1) Anticoagulant (2) Antimicrobial Cationic Peptides (1) Antiparasitic Agents (3) Antiviral (2) Ascorbic Acid (3) Calcifediol (1) Collagen (1) Coronavirus (2) COVID-19 (23) Dithiothreitol (1) Endothelial Barrier (1) Endothelial Permeability (1) Epidemiology (2) Ergocalciferols (1) Famotidine (7) Fixed drug eruption (1) Glucocorticosteroids (3) Heparanase (2) Human immunodeficiency virus (HIV) (1) Hydroxychloroquine (2) Inflammation (4) ivermectin (18) Melatonin (13) Methylprednisol (2) Nitric Oxide (1) Omicron (6) Onchocerciasis (1) pharmacokinetics (1) Pneumonia (2) SARS-CoV-2 (20) Sars-CoV2 (2) Sepsis (3) Septic (2) Spike Protein (5) Stevens–Johnson syndrome (SJS) (1) Tempol (1) viral infection (3) Vitamin C (3) Vitamin D (6) vitamin D 2 (1)

  • Reference: Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS-induced sepsis

    Published On: February 19, 2020

    Sepsis commonly progresses to disseminated intravascular coagulation and induces the activation of heparanase (HPA) and the shedding of endothelial glycocalyx constituents, including syndecan-1 (SDC-1) and heparan sulphate (HS). However, the degradation of glycocalyx and its association with coagulation disorders remains undetermined.

    Categories: I-PREVENT

    Tags: Glycocalyx, Heparanase, Septic